This article is property of Angel Aesthetics. Please do not share this without prior written consent.
Wegovy Tablets Have Arrived in the UK
What You Need to Know About Safe Weight Loss Treatment
Weight loss medications have transformed the way obesity is managed in the UK over recent years, offering new options for people who have struggled to achieve and maintain weight loss through lifestyle changes alone.
GLP-1 receptor agonists have become increasingly popular with growing public awareness driven by clinical research as well as media coverage and social media discussion. This summer the Medicines and Healthcare products Regulatory Agency (MHRA) approved the tablet formulation of semaglutide – Wegovy- for weight management in appropriate patients, providing an alternative to the established weekly injection.
Understanding Semaglutide: Ozempic vs Wegovy
Semaglutide is the active ingredient originally developed for the treatment of type 2 diabetes and is marketed under the brand name Ozempic for this purpose. Although Ozempic and Wegovy contain the same active ingredient and are manufactured by the same pharmaceutical company, Novo Nordisk, they are licensed for different uses. In the UK Wegovy is approved for weight management, whereas Ozempic remains licensed for type 2 diabetes. However, clinicians may prescribe medicines outside their licensed indication ‘off label’ where they consider this clinically appropriate and in the best interests of the patient.
How Does Semaglutide Work?
Semaglutide belongs to a group of medicines known as GLP-1 receptor agonists. It works by mimicking the action of a naturally occurring hormone involved in appetite regulation, digestion and blood glucose control. By activating GLP-1 receptors, semaglutide helps the brain recognise feelings of fullness, reducing appetite and helping to control cravings and the constant thoughts about food often described as “food noise”. It also slows gastric emptying, meaning food remains in the stomach for longer, helping patients feel fuller after meals, while improving blood sugar regulation. When combined with a balanced, calorie controlled diet, increased physical activity and long term lifestyle changes semaglutide can support significant weight loss for suitable patients. However, it is important to remember that semaglutide is a medical treatment rather than a replacement for healthy habits and best outcomes are achievedwith a holistic approach including diet, exercise and behaviouralchanges.
Tablets and Injections: What Is the Difference?
Wegovy is now available in both injectable and tablet formulations offering patients greater choice depending on their preferences, circumstances and clinical suitability. Early studies suggest that once daily oral semaglutide may provide weight loss results comparable with weekly injections, with some clinical trials reporting weight reductions of up to 17% from baseline. For some patients, particularly those who are uncomfortable with injections the tablet formulation may provide a more acceptable treatment option. The injectable formulation of Wegovy continues to be widely used within weight management services. On 3rd July 2026 it also received conditional approval for the treatment of Metabolic Associated Steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis as part of ongoing clinical evaluation, reflecting the expanding role of GLP-1 medicines beyond weight management. Treatment begins at a low dose and is gradually increased according to individual response and tolerance. This approach helps minimise gastrointestinal side effects such as nausea and vomiting. If treatment is stopped semaglutide gradually leaves the body over several weeks and appetite may return, and so without ongoing lifestyle support weight regain can occur.
The Impact of Weight Loss on Facial Appearance and Skin Quality
Weight loss can have a significant positive impact on overall health, mobility, confidence and quality of life. However, changes in body composition can also affect facial appearance, particularly when a large amount of weight is lost or when weight loss occurs quickly. The face naturally contains areas of fat that provide structure, support and youthful contours. During weight reduction a loss of facial volume may sometimes lead to a more hollow appearance around areas such as the cheeks, temples or undereye area. Some individuals may also notice changes in skin laxity or the visibility of lines and folds. These changes have become widely discussed online as “Ozempic face”. However, it is important to clarify that these changes are not caused by semaglutide itself but the result of the weight loss process and changes in facial fat. The extent of facial changes varies greatly between individuals and depends on many factors, including age, genetics, skin elasticity, sun exposure, smoking history, nutritional status, the amount of weight lost and the speed of weight reduction. Supporting skin health during weight loss is an important part of the overall journey. Adequate protein intake, hydration, resistance exercise and a balanced diet can all contribute to maintaining muscle mass and supporting skin quality. For some patients, aesthetic treatments such as dermal filler, Sculptra or thread lifts may help address concerns that arise following significant weight loss. A detailed consultation can help determine whether concerns relate primarily to volume loss, skin quality, collagen depletion or changes in skin laxity.Depending on individual needs, treatment options may include approaches that support collagen production, improve skin quality or restore volume in carefully selected areas. A personalised plan is essential, as each patient’s anatomy, ageing process, weight loss journey and goals are different. Treatment decisions should be guided by a thorough assessment and realistic expectations. Patients should also tell their aesthetic practitioner if they are taking semaglutide or any other prescription weight loss medication, as this may affect factors such as nutritional status, hydration and healing capacity.
UK Semaglutide Prescribing Guidelines
Semaglutide is a prescription only medicine (POM) and should only be prescribed following a thorough assessment by a suitably qualified healthcare professional. Private prescribing follows the licensed indication for Wegovy, rather than NICE guidelines, allowing access to treatment at a lower BMI and for longer durations.
Patients may be considered suitable if they have:
• A BMI of 30 kg/m² or above, or
• A BMI of 27 kg/m² or above with at least one weight related medical condition.
A private prescription should only be issued after a consultation that considers medical history, current medication, previous weight management attempts, and suitability for treatment.
Buying Semaglutide Safely
The increasing popularity of GLP-1 medications has unfortunately been accompanied by a rise in counterfeit and unregulated products. A simple online search for “Semaglutide UK” produces a large number of websites advertising tablets and injections, including discounted offers and products promoted through social media platforms. While some suppliers are legitimate others may be operating outside UK regulations and may place patients at significant risk. Semaglutide, like botulinum toxin, is a prescription only medicine and should only be supplied following an appropriate medical consultation.
A legitimate provider will:
• Complete a clinical assessment before prescribing.
• Review medical history and current medication.
• Discuss potential benefits, risks and side effects.
• Provide ongoing monitoring and support.
• Supply medication through a regulated pharmacy.
A consultation should never be viewed as an unnecessary barrier. It is a vital safety step that ensures the medication is appropriate and that risks are minimised. Research by ZAVA found that around one in five people using weight loss medication in the UK had not obtained their medication from a healthcare professional, while more than one in ten obtained weight loss medication through social media. If a price seems too good to be true, it often is. Genuine prescription medication is manufactured under strict quality standards and supplied through regulated pharmaceutical systems. Although some providers may offer introductory discounts or treatment packages, unusually low prices should always be approached with caution. Patients should ensure that their treatment is supplied through an appropriately regulated healthcare provider and dispensed by a pharmacy registered with the General Pharmaceutical Council (GPhC).
Why Medical Supervision Matters
All prescription medicines require appropriate clinical oversight, and semaglutide is no exception. Correct administration is essential for both safety and effectiveness and Wegovy tablets must be taken correctly to ensure they are absorbed properly.
The tablet should be taken:
• First thing in the morning after fasting for at least eight hours.
• With a small amount of water only.
• At least 30 minutes before eating, drinking anything else or taking other medication.
Taking the tablet with food, too much water or alongside other medication can affect absorption and may reduce the effectiveness of treatment. Common side effects include nausea, vomiting, diarrhoea and constipation. These effects are often most noticeable when starting treatment or increasing the dose and may improve as the body adapts. However, more serious side effects can occur, including:
• Severe allergic reactions such as anaphylaxis.
• Acute pancreatitis.
• Worsening diabetic retinopathy in susceptible individuals.
• Low blood sugar, particularly when used alongside certain diabetes medications.
Patients should seek medical advice if they experience severe or persistent symptoms. Suspected side effects should be reported through the MHRA Yellow Card Scheme which allows patients and healthcare professionals to report concerns about medicines and helps monitor ongoing safety.
Medication Interactions and Procedures
Weight loss can be a personal and sensitive subject and some patients may choose not to disclose that they are taking semaglutide. However this information is important for all healthcare professionals involved in your care. Semaglutide can affect the absorption of some oral medicines because it slows gastric emptying. Medications such as Warfarin and Levothyroxine may require additional monitoring. It is also important before any procedure involving sedation or general anaesthetic, as delayed stomach emptying may increase certain risks. Always inform your GP, pharmacist, dentist, surgeon, anaesthetist and aesthetic practitioner if you are taking semaglutide or any other weight loss medication.
How to Spot Fake Semaglutide
Counterfeit medicines are becoming increasingly sophisticated making it harder for patients to identify unsafe products. The safest way to protect yourself is to only purchase Wegovy from a reputable healthcare provider following a genuine consultation and prescription.
Be cautious of suppliers that:
• Advertise unusually low prices.
• Sell medication through social media or messaging apps.
• Use pressure selling techniques.
• Request payment through unusual methods such as cryptocurrency.
• Promote “generic Wegovy”, “Wegovy-like” products or “DIY Ozempic”.
• Contain poor spelling, grammar or unclear registration details.
Legitimate pharmacies should clearly display their registration information, which can be checked through the General Pharmaceutical Council register.
Packaging and Product Checks
Genuine Wegovy and Ozempic products are manufactured by Novo Nordisk and contain specific packaging and security features.
Medication packaging should:
• Be intact and professionally printed.
• Include clear batch numbers and expiry dates.
• Contain appropriate tamper evident seals.
• Include required security features such as 2D barcodes.
Wegovy tablets should remain sealed in their original packaging and should never arrive loose, as powder or in unidentified containers. Counterfeit tablets have been found to containincorrect doses of semaglutide, no active medication at all, or harmful substances. Counterfeit injectable products have been found to contain insulin, alternative medications or simply water. There have also been reports of unlabelled pre-filled syringes being sold as Wegovy, which should never be used.
What Should You Do If You Are Concerned?
If you have concerns about your medication, whether related to side effects, possible interactions or whether the product is genuine, it is important to seek advice promptly. Contact your prescribing clinician or pharmacist for guidance and do not continue using a product if you are concerned that it may not be authentic. If you become acutely unwell after taking semaglutide, seek urgent medical advice through your GP, NHS 111, your nearest Emergency Department or by calling 999 in an emergency.
Suspected counterfeit or falsified medicines should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA).
Reporting helps authorities investigate unsafe products and prevent them from reaching other patients.
Report a suspected problem with a medicine or medical device:
https://www.gov.uk/report-problem-medicine-medical-device
If you see prescription only medicines being advertised or sold illegally through social media platforms these accounts can also be reported directly to the platform.
Useful links
NHS Wegovy information:
https://www.nhs.uk/medicines/wegovy/
MHRA Yellow Card Scheme:
https://yellowcard.mhra.gov.uk/
General Pharmaceutical Council Register:
https://www.pharmacyregulation.org/registers
Final Thoughts
Semaglutide has transformed the management of obesity and represents one of the most significant advances in weight management in recent years. The availability of both injectable and tablet formulations provides greater choice and may allow more patients to access a treatment option that suits their individual needs. However semaglutide is not a ‘quick fix’ and should not be viewed as a replacement for healthy lifestyle changes. The best outcomes are achieved when medication is combined with nutritional support, physical activity, behaviouralchanges and ongoing clinical monitoring. Safe prescribing is essential including obtaining medication through regulated healthcare providers, following correct administration guidanceand attending regular reviews all contribute to achieving the safest and most effective results. For patients considering weight loss medication, the most important first step is a consultation with a qualified healthcare professional who can assess suitability, discuss expectations and provide personalisedadvice. At every stage of the weight loss journey, informed decisions, evidence-based treatment and appropriate supportremain key to achieving sustainable results.
Medical Disclaimer
This article is intended for general information purposes only and should not be considered medical advice.